Acomplia Update
"As if all that weren't enough, FDA approval for the company's long-awaited anti-obesity treatment, Acomplia, has been delayed until next spring. "It's just the latest setback for a volatile company that's struggling with a lot of issues," says Navid Malik, a pharmaceutical analyst with London-based brokerage Collins Stewart.
With troubles mounting, Sanofi is under intense pressure to get Acomplia onto the U.S. market—fast. Hailed by analysts as a potential multibillion-dollar blockbuster, Acomplia is critical to the company's future growth. Also known as rimonobant, the drug is the first in a new class of medicines that curtail cravings by blocking receptors known as cannabinoid type 1 (CB1) found in the brain and in fat tissue. CB1 receptors influence hunger and addictions, such as to nicotine.
Clinical trials indicate that Acomplia not only could help people lose weight but also shrink abdominal fat and help them stop smoking. Even more remarkably, it can also improve cholesterol levels and blood-sugar control. That means Acomplia might also someday be used in treating diabetes, though approval for that application remains years off, pending results of tests now under way. "
acomplia
rimonabant
accomplia
0 Comments:
Post a Comment
<< Home